Terms: = Skin cancer AND Ki-67 AND Clinical Outcome
21 results:
1. Proliferative Tumor-Infiltrating Lymphocytes' Abundance within the Microenvironment Impacts clinical outcome in Cutaneous B-Cell Lymphomas.
Menguy S; Prochazkova-Carlotti M; Azzi-Martin L; Ferté T; Bresson-Bepoldin L; Rey C; Vergier B; Merlio JP; Beylot-Barry M; Pham-Ledard A
J Invest Dermatol; 2023 Jan; 143(1):124-133.e3. PubMed ID: 35970476
[TBL] [Abstract] [Full Text] [Related]
2. Expression of MCM2 as a Proliferative Marker in Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.
Rymsza A; Świerczyńska K; Piotrowska A; Dzięgiel P; Szepietowski JC
In Vivo; 2022; 36(3):1245-1251. PubMed ID: 35478139
[TBL] [Abstract] [Full Text] [Related]
3. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
Nielsen PS; Riber-Hansen R; Steiniche T
Pathology; 2018 Jun; 50(4):402-410. PubMed ID: 29678478
[TBL] [Abstract] [Full Text] [Related]
5. Merkel cell carcinoma: mitoses, expression of ki-67 and bcl-2 correlate with disease progression.
Vujic I; Marker M; Posch C; Mühlehner D; Monshi B; Breier F; Steiner A; Ortiz-Urda S; Rappersberger K
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):542-8. PubMed ID: 25088273
[TBL] [Abstract] [Full Text] [Related]
6. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.
Wilmott JS; Haydu LE; Menzies AM; Lum T; Hyman J; Thompson JF; Hersey P; Kefford RF; Scolyer RA; Long GV
J Immunol; 2014 Mar; 192(5):2505-13. PubMed ID: 24489105
[TBL] [Abstract] [Full Text] [Related]
7. Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma.
Lim CS; Whalley D; Haydu LE; Murali R; Tippett J; Thompson JF; Hruby G; Scolyer RA
Ann Surg Oncol; 2012 Oct; 19(11):3325-34. PubMed ID: 22820936
[TBL] [Abstract] [Full Text] [Related]
8. Association between gene expression profile, proliferation and metastasis in uveal melanoma.
Onken MD; Worley LA; Harbour JW
Curr Eye Res; 2010 Sep; 35(9):857-63. PubMed ID: 20795869
[TBL] [Abstract] [Full Text] [Related]
9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract] [Full Text] [Related]
10. Primary dermal melanoma: distinct immunohistochemical findings and clinical outcome compared with nodular and metastatic melanoma.
Cassarino DS; Cabral ES; Kartha RV; Swetter SM
Arch Dermatol; 2008 Jan; 144(1):49-56. PubMed ID: 18209168
[TBL] [Abstract] [Full Text] [Related]
11. ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.
Pearl RA; Pacifico MD; Richman PI; Stott DJ; Wilson GD; Grobbelaar AO
J Exp Clin Cancer Res; 2007 Mar; 26(1):109-15. PubMed ID: 17550139
[TBL] [Abstract] [Full Text] [Related]
12. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Jørgensen K; Davidson B; Flørenes VA
Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
[TBL] [Abstract] [Full Text] [Related]
13. ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.
Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S
Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864
[TBL] [Abstract] [Full Text] [Related]
14. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome.
Woenckhaus C; Maile S; Uffmann S; Bansemir M; Dittberner T; Poetsch M; Giebel J
Histol Histopathol; 2005 Apr; 20(2):501-8. PubMed ID: 15736055
[TBL] [Abstract] [Full Text] [Related]
15. Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome.
Flørenes VA; Maelandsmo GM; Holm R; Reich R; Lazarovici P; Davidson B
Am J Clin Pathol; 2004 Sep; 122(3):412-20. PubMed ID: 15362372
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract] [Full Text] [Related]
17. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract] [Full Text] [Related]
18. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
[TBL] [Abstract] [Full Text] [Related]
19. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions.
Tran TA; Ross JS; Carlson JA; Mihm MC
Hum Pathol; 1998 Oct; 29(10):1085-90. PubMed ID: 9781646
[TBL] [Abstract] [Full Text] [Related]
20. p53-protein and ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract] [Full Text] [Related]
[Next]
